Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 1

Conditions

Cancer
Solid Tumors
Advanced Solid Malignancies

Treatments

Drug: AZD8055

Study type

Interventional

Funder types

Industry

Identifiers

NCT00973076
D1600C00003

Details and patient eligibility

About

The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.

Enrollment

19 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Japanese patients with advanced solid tumors for which suitable effective standard treatment does not exist or is no longer effective
  • Relatively good overall health other than cancer

Exclusion criteria

  • Poor bone marrow function (not producing enough blood cells)
  • Poor liver or kidney function
  • Serious concomitant illness

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

19 participants in 1 patient group

AZD8055
Experimental group
Description:
AZD8055 will be administered orally
Treatment:
Drug: AZD8055

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems